TNF and inflammatory bowel disease: Moreover, even though studies on IBD patients have not reported a higher prevalence of COVID-19 compared to the general population, IBD-related use of glucocorticoids (but not anti-TNF-alpha treatment) may be associated with a higher risk of a more severe COVID-19 infection in this subgroup of gastroenterological patients [32,33,34].